Treatment in juvenile rheumatoid arthritis and new treatment options

Creative Commons License

Kasapcopur O., Barut K.

TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS, cilt.50, sa.1, ss.1-10, 2015 (ESCI, Scopus, TRDizin) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 50 Sayı: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.5152/tpa.2015.2229
  • Dergi Adı: TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-10
  • Anahtar Kelimeler: Adalimumab, anakinra, anti-TNF agents, pediatric rheumatology, etanercept, infliximab, juvenile idiopatic arthritis, kanakunimab, treatment, PLACEBO-CONTROLLED TRIAL, IDIOPATHIC ARTHRITIS, DOUBLE-BLIND, PRELIMINARY CRITERIA, SELECT CATEGORIES, CHILDREN, SAFETY, EFFICACY, ETANERCEPT, MULTICENTER
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Juvenile idiopathic arthritis (JIA) is the most common chronic rehumatic disease of the childhood with the highest risk of disability. Active disease persists in the adulthood in a significant portion of children with juvenile rheumatoid arthritis despite many developments in the diagnosis and treatment. Therefore, inititation of efficient treatment in the early period of the disease may provide faster control of the inflammation and prevention of long-term harms. In recent years, treatment options have also increased in children with juvenile idiopathic arthritis owing to biological medications. All biological medications used in children have been produced to target the etiopathogenesis leading to disease including anti-tumor necrosis factor, anti-interleukin 1 and anti-interleukin 6 drugs. In this review, the scientific data related with use of biological drugs in juvenile rheumatoid arthritis will be reviewed in detail and new treatment options will be reviewed.